Jump to content

Martin Shkreli

From Wikipedia, the free encyclopedia
(Redirected from Retrophin)

Martin Shkreli
Shkreli in 2016
Born (1983-03-17) March 17, 1983 (age 41)[2]
Brooklyn, New York City, U.S.
EducationBaruch College (BBA)
Occupation(s)Investor, Fintech Software developer, YouTuber, former hedge fund manager and biotech founder
Known forTuring Pharmaceuticals, Retrophin, Daraprim price hike
Criminal statusReleased
Conviction(s)Securities fraud (18 U.S.C. § 1348) (2 counts)
Conspiracy to commit securities fraud (18 U.S.C. § 1348)
Criminal penalty7 years in prison (paroled after 6 years and 5 months)[1]
$7.4 million in fines
YouTube information
Channel
Genre(s)Investing, finance
Subscribers59.3 thousand[3][4]
Total views1.88 million[4]
Last updated: May 01, 2024

Martin Shkreli (/ˈʃkrɛli/; born March 17, 1983) is an American investor and businessman. Shkreli is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare, the co-founder and former CEO of pharmaceutical firms Retrophin and Turing Pharmaceuticals, and the former CEO of start-up software company Gödel Systems, which he founded in August 2016.

In September 2015, Shkreli was widely criticized when Turing obtained the manufacturing license for the antiparasitic drug Daraprim and raised its price to insurance companies from $13.50 to $750.00 (USD) per pill.

In 2017, Shkreli was convicted in federal court on two counts of securities fraud and one count of conspiracy. He was sentenced to seven years in prison and up to $7.4 million in fines. In the civil antitrust case, Shkreli was fined a further $64.6 million to be repaid to victims. In May 2022, he was released early from the low-security federal prison in Allenwood, Pennsylvania. He is permanently banned from serving as an officer of any publicly traded company.

Early life

[edit]

Shkreli was born in Coney Island Hospital in the New York City borough of Brooklyn on March 17, 1983.[5][6] His parents were Roman Catholic, and he said his religion has been "a guiding post" for him, although he does not believe in God.[7] His parents immigrated to the United States from Albania and worked as janitors.[8] He, his two sisters, and his brother grew up in a working-class community in Sheepshead Bay, Brooklyn.[9][10][11] Shkreli was raised Catholic and attended Sunday school as a child.[12] Shkreli attended Hunter College High School. Sources differ on whether Shkreli graduated from Hunter[11] or whether he was expelled before his senior year and received the credits necessary for his high school diploma through City-As-School High School.[13][14] He ended up in a program that placed him in an internship at Wall Street hedge fund Cramer, Berkowitz and Company when he was 17.[10][15] Shkreli received a bachelor's degree in business administration from Baruch College in 2004.[16]

Shkreli told Vanity Fair that he developed an interest in chemistry when a family member suffered from treatment-resistant depression.[6]

Career

[edit]

During Shkreli's time at Cramer, Berkowitz and Company, he recommended short-selling the stock of Regeneron Pharmaceuticals, a biotech company testing a weight-loss drug. When its price dropped in accordance with Shkreli's prediction, Cramer's hedge fund profited. Shkreli's prediction drew the attention of the Securities and Exchange Commission, which investigated Shkreli's knowledge about the stock but was unable to prove wrongdoing on his part.[17]

MSMB Capital Management

[edit]

After four years as an associate at Cramer Berkowitz, Shkreli worked as a financial analyst for Intrepid Capital Management and UBS Wealth Management.[18] He then started his first hedge fund, Elea Capital Management, in 2006.[15][19] In 2007, Lehman Brothers sued Elea in New York state court for failing to cover a 'put option transaction' in which Shkreli bet the wrong way on a broad market decline. When stocks rose, Shkreli did not have the money to cover his losses. In October 2007, Lehman Brothers won a $2.3 million default judgment against Shkreli and Elea, but Lehman collapsed before it could collect on the ruling.[17]

In September 2009, Shkreli and a childhood friend Marek Biestek started MSMB Capital Management,[8][20] which took its name from the initials of the two.[15][17] Shkreli and Biestek shorted biotech companies, then described flaws in the companies on stock trading chat rooms.[6]

On February 1, 2011, in a naked short sale on an account it held with Merrill Lynch, MSMB Capital sold short 32 million shares of Orexigen Therapeutics stock at about $2.50 per share the day after its price plunged from $9.09, when the Food and Drug Administration (FDA) declined to approve the drug naltrexone/bupropion (Contrave).[21][22] The stock price rebounded; MSMB could not cover the position, although it had told Merrill Lynch that it could.[23] Merrill Lynch lost $7 million on the trade and MSMB Capital was virtually wiped out. Retrophin's 2015 SEC Complaint contended Shkreli had created MSMB Healthcare and Retrophin "so that he could continue trading after MSMB Capital became insolvent and to create an asset that he might be able to use to placate his MSMB Capital investors."[24]

In 2011, Shkreli filed requests with the FDA to reject a new cancer diagnostic device from Navidea Biopharmaceuticals and an inhalable insulin therapy from MannKind Corporation while publicly short-selling both companies' stocks, the values of which dropped after Shkreli's interventions. The companies had difficulty launching the products as a result, although the FDA ultimately approved both.[17][25][26]

In 2011, MSMB made an unsolicited cash bid for AMAG Pharmaceuticals at a price of $378 million.[27] Matthew Herper of Forbes wrote that the attempted hostile takeover was "done for the specific purpose of firing the company's management and stopping a proposed merger with Allos Therapeutics. When the merger plans stopped, so did Shkreli."[28]

Retrophin

[edit]
Retrophin Inc
Nasdaq: RTRX
Russell 2000 Index component

Shkreli founded Retrophin (a portmanteau of "Recombinant dystrophin") in 2011 under the MSMB umbrella and ran it as a portfolio company with an emphasis on biotechnology, to create treatments for rare diseases.[17][29][30][31]

In November 2013, Shkreli was chosen for the Forbes 30 Under 30.[32] The publication regretted it ten years later, placing Shkreli in its "Hall of Shame", a list of ten notably bad picks.[33][34]

Retrophin's board decided to replace Shkreli in September 2014, and he resigned from the company the following month.[24] He was replaced by Stephen Aselage.[35] During Shkreli's tenure as CEO, the company's employees used alias Twitter accounts to make gangster rap jokes and encourage short selling of other biotech stocks.[36]

After Shkreli's departure, Retrophin filed a US$65 million lawsuit against him in August 2015, claiming that he had breached his duty of loyalty to the biopharmaceutical company in a long-running dispute over his use of company funds[24][30][37] and "committed stock-trading irregularities and other violations of securities rules."[38] The lawsuit alleged that Shkreli had threatened and harassed a former MSMB employee and his family.[39]

Shkreli and some of his business associates have been under criminal investigation by the U.S. Attorney for the Eastern District of New York since January 2015. Shkreli invoked his Fifth Amendment right against self-incrimination in order to avoid testifying during civil depositions.[40][41]

Shkreli's name is on two patents held by Retrophin for drugs to treat PKAN.[6][42]

In November 2020, Eric Dube, Retrophin's new chief executive, announced the company would be rebranded as Travere Therapeutics Inc. in an effort to further distance the company from Shkreli, and said the company is no longer working on treatments for the disease from which the company takes its name.[43]

Views on Shkreli's leadership

[edit]

In July 2017, at Shkreli's criminal trial, Aselage, who was hired by Shkreli in October 2012, and replaced him at Retrophin in 2014, testified "He's a brilliant intellect, visionary" but also someone who was called a "Pied Piper" and whom Aselege "worried about not always getting 'straight answers' from".[44]

Thiola price hike

[edit]

In May 2014, Shkreli had difficulty accessing public markets for capital, but received a $4 million series A funding round and a PIPE deal valued at $10 million underwritten by Roth Capital Partners.[45] After obtaining the financing, Shkreli was able to acquire rights to market tiopronin (brand name Thiola), a drug used to treat the rare disease cystinuria, and another drug Chenodal, and subsequently raised the price of each drug substantially, with Thiola being marked up about 20 fold, from $1.50 to $30 per pill (patients must take 10 to 15 pills a day),[46][47] and Chenodal about fivefold.[48] Retrophin did not lower the price of these drugs after Shkreli's departure.[49]

In 2016, Imprimis Pharmaceuticals introduced a lower cost version of Thiola marketed as a compounded drug.[50]

Turing Pharmaceuticals

[edit]

Shkreli founded Turing Pharmaceuticals in February 2015, after his departure from Retrophin. He launched Turing with three drugs in development acquired from Retrophin: An intranasal version of ketamine for depression, an intranasal version of oxytocin, and Vecamyl for hypertension.[51] Shkreli set a business strategy for Turing: To obtain licenses on out-of-patent medicines, and reevaluate the pricing of each in pursuit of windfall profits for the new company, without the need to develop and bring its own drugs to market.[52][53] As markets for out-of-patent drugs are often small, and obtaining regulatory approval to manufacture a generic version is expensive, Turing calculated that with closed distribution for the product and no competition, it could set high prices.[52]

Daraprim price hike

[edit]

On August 10, 2015, in accordance with Shkreli's business plan, Turing acquired Daraprim (pyrimethamine), a medication approved by the FDA in 1953,[54] from Impax Laboratories[55] for US$55 million.[56] The drug's most prominent use as of late 2015 was as an anti-malarial[57] and an antiparasitic, in conjunction with leucovorin and sulfadiazine,[58] to treat patients with both AIDS-related and AIDS-unrelated toxoplasmosis.[59]

The patent for Daraprim had expired, but no generic version was available.[60] The Turing–Impax deal included the condition that Impax remove the drug from regular wholesalers and pharmacies,[57] and so in June 2015, two months before the sale to Turing was announced, Impax switched to tightly controlled distribution.[15] In keeping with its strategy for pricing in the face of limited competition, Turing maintained the closed distribution.[52] The New York Times said that the deal "made sense only if Turing planned to raise the price of the drug substantially."[15]

On September 17, 2015, Dave Muoio of Healio, an in-depth clinical information website for health care specialists,[61] reported on a letter from the Infectious Diseases Society of America and the HIV Medicine Association to executives at Turing,[62] questioning a new pricing for Daraprim.[59] The price of a dose of the drug in the U.S. market increased by a factor of 56 (from US$13.50 to US$750 per pill) overnight.[63]

The price increase was initially criticized, jointly, by the Infectious Diseases Society of America and the HIV Medicine Association,[57][62] by the Pharmaceutical Research and Manufacturers of America,[64] and soon thereafter by presidential candidates Hillary Clinton,[65] Bernie Sanders,[66] and Donald Trump.[67]

A subsequent organized effort called on Turing to return pricing to pre-September levels and to address several matters relating to the needs of patients, an effort that garnered endorsements from more than 160 medical‑specialty and patient‑related organizations (as of December 2015, 164 organizations from 31 states, the District of Columbia, and Puerto Rico).[68][69]

In response to the controversy, the record label Collect Records publicly ended its business relationship with Shkreli, who had invested in the company.[70]

In a September 2015 interview with Bloomberg Markets, Shkreli said that despite the price increase, patient co-pays would actually be lower, that many patients would get the drug at no cost, that Turing had expanded its free drug program, and that it sold half of its drugs for one dollar.[71] He defended the price hike by saying, "If there was a company that was selling an Aston Martin at the price of a bicycle, and we buy that company and we ask to charge Toyota prices, I don't think that that should be a crime."[72][73]

A few days later, Shkreli announced that he planned to lower the price by an unspecified amount, "in response to the anger that was felt by people."[40] But in late November, Turing reversed course and said it would not lower the price after all.[74]

Following a request by Senator Bernie Sanders and Representative Elijah Cummings for details of Turing Pharmaceuticals' finances and price-setting practices in September 2015,[75][76] the company hired four lobbyists from Buchanan, Ingersoll & Rooney with backgrounds in health care legislation and pharmaceutical pricing.[77][78] In addition to lobbyists, Shkreli hired a crisis public relations firm to help explain the pricing decision.[79]

On October 22, 2015, Mark L. Baum, CEO of Imprimis Pharmaceuticals, announced that his company would provide a combination product containing pyrimethamine (the active ingredient in Daraprim) and leucovorin at "$1-a-pill" as a cheaper and more efficient alternative to Daraprim.[80] This product was intended to be used alongside sulfadiazine in the standard protocol to treat toxoplasmosis typically seen in AIDS patients.[59]

Baum said, "This is not the first time a sole supply generic drug – especially one that has been approved for use as long as Daraprim – has had its price increased suddenly and to a level that may make it unaffordable." He announced the availability of the compounded replacement for Daraprim as a part of a larger corporate program, "Imprimis Cares." to make "novel and customizable medicines available to physicians and patients at accessible prices." Imprimis began selling its compounded, orally taken formulations of pyrimethamine and leucovorin at US$99 for a 100 count bottle, essentially a dollar a dose.[80]

On November 23, 2015, Turing announced that the company would not reduce the list price of Daraprim, but said it planned instead to negotiate volume discounts of up to 50% for hospitals.[81] Turing issued a statement that it was not as important to cut the list price as to reduce the cost to hospitals, where most patients get their initial treatment. The company pledged that no patient needing Daraprim would ever be denied access.[74]

Infectious disease specialists and patient advocates, including Tim Horn of the Treatment Action Group and Carlos del Rio of the HIV Medicine Association, said Turing's actions were insufficient, given that patients initially treated for days at a hospital typically have to continue the treatment for weeks or months after leaving.[82]

Vyera/Phoenixus

[edit]

After Shkreli was imprisoned, Turing changed its name to Vyera in 2017[83] to avoid negative publicity, and in 2019 was called Phoenixus AG. In March 2019, The Wall Street Journal reported that Shkreli "steers his old company from prison."[84] Using a contraband cellphone from his prison ward in Fort Dix, New Jersey, Shkreli was effectively directing the renamed firm, and was reported to have terminated the employment of executive Kevin P. Mulleady.[85] After this news was reported in various news outlets, Shkreli was moved to the Metropolitan Detention Center in Brooklyn in advance of a subsequent move to a federal prison in Pennsylvania.[86] He was also facing a Bureau of Prisons investigation into his breaking federal prison rules, since federal inmates are prohibited both from running a business from prison and from possessing cell phones.[87]

In May 2023, Vyera Pharmaceuticals declared Chapter 11 bankruptcy in Delaware court, listing between $10 million and $50 million in assets and between $1 million and $10 million in liabilities. The company cited "declining profits, increased competition for generic drugs, and litigation alleging that Vyera suppressed competition for its most valuable drug, Daraprim" per Reuters. Shkreli's shares in Vyera had earlier been ordered seized by federal court related to an FTC judgment against him.[88]

FTC v. Vyera Pharmaceuticals

[edit]

In January 2020 the FTC filed a case against Vyera "alleging an elaborate anticompetitive scheme to preserve a monopoly for the life-saving drug, Daraprim".[89] A settlement was reached in December 2021. According to AP News, the settlement "requires Vyera and Phoenixus to provide up to $40 million in relief over 10 years to consumers who allegedly were fleeced by their actions and requires them to make Daraprim available to any potential generic competitor at the cost of producing the drug."[90] Kevin Mulleady "agreed to a seven-year ban on working for or holding more than an 8% share in most pharmaceutical companies."[91]

KaloBios Pharmaceuticals

[edit]

In November 2015, an investor group led by Shkreli acquired a majority stake in KaloBios Pharmaceuticals (OTC Pink Limited: KBIOQ), a biopharmaceutical company based in South San Francisco, California.[92] Shkreli was named CEO of the company and also planned to continue in the role of CEO of Turing Pharmaceuticals.[93][94] After his December 2015 arrest, KaloBios Pharmaceuticals terminated him as CEO.[95] On December 29, 2015, KaloBios filed for Chapter 11 bankruptcy. This followed NASDAQ delisting its shares, and the resignation of two directors.[96]

Gödel Systems, Inc

[edit]

Shkreli founded Gödel Systems in August 2016 as "a professional software company that aims to be the leading information provider of data, workflow, and communications solutions for financial, law, and scientific professionals." By February 2017, Gödel Systems was looking to raise $1 million through a debt offering, and had raised $50,000 out of the $1 million in debt it began issuing in mid-January 2017, according to regulatory filings. Ralph Holzmann, a former senior engineer at Twitter, is the firm's chief technology officer.[citation needed]

Druglike and Martin Shkreli Inu coin

[edit]

Following his release from prison, in 2022, a planned software platform named Druglike controlled by Shkreli was announced with a stated aim of supporting the development of new pharmaceutical drugs.[97] A related cryptocurrency project, the Martin Shkreli Inu coin, had been launched but in August lost 90% of its value (recovering shortly afterwards to a 55% loss) after an account believed to belong to Shkreli sold its Inu coin holdings. An account believed to belong to Shkreli claimed, in explanation, to have been hacked.[98]

Testimony before Congress

[edit]

Shkreli was subpoenaed to appear before the Committee on Oversight and Government Reform of the U.S. House of Representatives to answer questions about the Daraprim price increase.[99] Shkreli's efforts to quash the subpoena were unsuccessful.[99]

On February 4, 2016, Shkreli appeared before the House committee,[100] along with Nancy Retzlaff,[101] the Chief Commercial Officer of Turing, and Howard B. Schiller, the interim CEO of Valeant.[102]

Accompanied by his attorney Benjamin Brafman, Shkreli invoked his Fifth Amendment privilege against self-incrimination in response to every question from committee members except for two: one from Representative Trey Gowdy to confirm the pronunciation of his last name, and another from Representative Elijah Cummings to affirm he was listening.[103][104] Shkreli also refused to answer even seemingly trivial questions outside the subject matter of the hearing, including those pertaining to his purchase of a Wu-Tang Clan album.[105][106] Following Cummings's rebuke of Shkreli, Chairman Jason Chaffetz dismissed Shkreli from the hearing.

Criminal conviction

[edit]

Investigation and charges

[edit]

On December 17, 2015, Shkreli was arrested by the FBI after a federal indictment in the U.S. District Court for the Eastern District of New York was filed, charging him with securities fraud. The charges were filed after an investigation into his tenure at MSMB Capital Management and Retrophin. U.S. Attorney Robert Capers said, "Shkreli essentially ran his company like a Ponzi scheme where he used each subsequent company to pay off defrauded investors from the prior company."[107]

Federal prosecutors said that Shkreli and co-defendant, Evan Greebel, "engaged in multiple schemes to ensnare investors through a web of lies and deceit."[108][109] In an interview with The Wall Street Journal, Shkreli said that he was targeted by law enforcement for his price hikes of the drug Daraprim and his flamboyant personality.[110]

In early 2016, Shkreli retained criminal defense attorney Benjamin Brafman to defend him.[111][112] Due to Shkreli's notoriety and overwhelmingly negative public opinion, it was difficult to select an unbiased jury.[113] At his 2017 trial, Shkreli argued that none of his investors actually lost money (some actually turned a profit) and thus his actions did not constitute a crime.[114] Shkreli's frequent criticisms of the federal prosecutors in New York's Eastern District, whom he called "junior varsity" compared to their counterparts in the Southern District across the East River, both on his Facebook streaming video feed and in the hallways of the courthouse, led those prosecutors to request that judge Kiyo A. Matsumoto issue a gag order to prevent what they called a "campaign of disruption". Brafman said in response that his client was responding to baiting from the media and was also suffering from extreme anxiety because of his situation.[115] Matsumoto ordered Shkreli not to speak with reporters, either in the courthouse or its immediate vicinity.[116]

Trial, conviction, and sentencing

[edit]

On August 4, 2017, the trial jury found Shkreli guilty on two counts of securities fraud and one count of conspiracy to commit securities fraud, and not guilty on five other counts which included wire fraud.[117] Shkreli said he was delighted with the outcome and described his prosecution as "a witch hunt of epic proportions".[118]

On September 13, 2017, his bail was revoked following a Facebook post offering $5,000 for a strand of Hillary Clinton's hair which the judge perceived as solicitation to assault, which is not protected under the First Amendment.[119] Shkreli's post was preceded by others that suggested he might have plans to clone Hillary Clinton.[120] Shkreli said that his post was satire, and his lawyer described it as tasteless but not a threat.[120] Shkreli edited the post to add a disclaimer that it was satire,[121] and later said he did this minutes after publication.[122] Shkreli apologized for the post.[123] He was sent to the Metropolitan Detention Center, Brooklyn[124] while awaiting sentencing.[123][125]

On March 9, 2018, Shkreli was sentenced to seven years in federal prison.[126][127] During his sentencing, Judge Kiyo A. Matsumoto said Shkreli seemed "genuinely remorseful" regarding his "egregious multitude of lies" but faulted him for having "repeatedly minimized" his misconduct. Shkreli, who cried as he gave his statement to the court, stated "I was never motivated by money."[128]

In 2019, Shkreli lost his appeal; the U.S. Court of Appeals for the Second Circuit unanimously affirmed the conviction in a seven-page ruling.[129][130] The original judgment remained in effect: Shkreli was required to continue to serve his seven-year sentence and forfeit more than $7.3 million in assets.[130][129]

Forfeiture of assets

[edit]

On March 5, 2018, Shkreli was ordered to forfeit nearly $7.4 million in assets.[131] The court ordered that if Shkreli had insufficient cash to fulfill the forfeiture order, his assets, including a piece of art by Pablo Picasso, would be sold to do so. Shkreli purchased the 31-track Wu-Tang Clan album Once Upon a Time in Shaolin (of which a single copy exists) at an auction in 2015 for around $2 million, as well as the then-unreleased Lil Wayne album Tha Carter V.[132] In April 2018, he was ordered to pay $388,000 in restitution.[133]

In July 2021, the United States government auctioned off the Wu-Tang Clan album bought by Shkreli to PleasrDAO for $4 million USD.[134] Jacquelyn M. Kasulis, the acting United States Attorney for the Eastern District of New York, said "Shkreli has been held accountable and paid the price for lying and stealing from investors to enrich himself", and "With today's sale of this one-of-a-kind album, his payment of the forfeiture is now complete."[135]

Incarceration

[edit]

Shkreli was federal inmate number 87850-053 and was first held at the Metropolitan Detention Center, Brooklyn, prior to being transferred to federal prison.[136] On March 27, 2018, it was reported that Judge Kiyo Matsumoto agreed to recommend Shkreli serve his prison sentence at the minimum-security federal camp at USP Canaan, which he had previously requested.[137][138] On April 18, 2018, Shkreli was transferred from Metropolitan Detention Center, Brooklyn, to FCI Fort Dix (a low-security facility) after his request to serve at Canaan was denied.[124] Shkreli was later transferred to FCC Allenwood.[139]

On September 6, 2019, several media outlets reported that Shkreli had leveled a lawsuit in a Brooklyn court claiming he had been fraudulently persuaded by a former investor in his Elea Capital fund to sign a promissory note that "left him owing $420,000 to the man's father."[140][141] Also in 2019, he was transferred to solitary confinement for a time, after prison authorities discovered he was using a contraband smartphone to conduct business from prison.[142] While incarcerated, he began a relationship with reporter Christie Smythe, leading to their engagement during his imprisonment.[143][144]

Shkreli asked the court for compassionate release in April 2020, saying that he should be allowed to live at the New York City apartment of his then-fiancée (later identified as former Bloomberg reporter Christie Smythe) and that his firm needed him to develop a remedy for COVID-19. Judge Matsumoto denied the request and said it was another instance of "delusional self-aggrandizing behavior" by Shkreli.[145][146][147]

Release

[edit]

On May 18, 2022, Shkreli was released from the Allenwood prison and transferred to a Bureau of Prisons halfway house; according to Shkreli's lawyer Brafman, Shkreli was released after "completing all programs that allowed for his prison sentence to be shortened."[139][148] He lived in the halfway house until September 2022; after his release, he lived with his sister in Queens and earned $2,500 per month as a consultant for a small law firm.[149][150] In his Substack, Shkreli wrote that he did the consulting "as a favor, to a friend" and did not "live on $2,500 a month" but rather had an additional salary in a "main day job" for DL Software, as well as income from other software ventures.[151]

Civil penalties and industry bans

[edit]

In December 2016, the New York State Department of Taxation and Finance issued a tax warrant against Shkreli for $1.26 million for unpaid taxes. He made partial payments and the State recovered another $134,500 from the auctioning off of various assets seized from Shkreli; these included an Enigma machine for $65,000, a manuscript signed by Isaac Newton, and letters from Charles Darwin and Ada Lovelace.[152]

In April 2018, New York's attorney general asked Judge Matsumoto for priority on more than $480,000 out of the $7.4 million in assets forfeited to the federal government, arguing that the state had priority over the federal government's claims for Shkreli's forfeited assets.[152]

In April 2018, Shkreli agreed to a Securities and Exchange Commission order banning him from the securities industry in exchange for settlement of the SEC administrative action against him; Shkreli is eligible to apply for readmission to the industry.[152]

In 2020, the Federal Trade Commission and seven states—California, Illinois, New York, North Carolina, Ohio, Pennsylvania, and Virginia—filed a civil lawsuit against Shkreli.[153] A seven-day bench trial was held in December 2021.[153] In January 2022, Judge Denise Cote of the U.S. District Court for the Southern District of New York issued a lengthy opinion and order directing Shkreli to return $64.6 million in wrongfully obtained profits (disgorgement); the money is to be distributed to victims nationwide (via the states that were plaintiffs in the case). The court found that Shkreli had violated federal and state law through an anticompetitive scheme to delay "the entry of generic competition for at least eighteen months" and banned Shkreli from the pharmaceutical industry for life.[153][154][155] The fine was upheld on appeal by both the Court of Appeals for the Second Circuit and the Supreme Court denied to hear his appeal from that decision.[156]

On February 23, 2022, U.S. District Judge Kiyo Matsumoto of the U.S. District Court for the Eastern District of New York ordered Shkreli to pay a $1.39 million fine for violating securities laws between 2009 and 2014 and banned from serving as an officer or a director of any publicly traded company for life.[157][158]

Net worth

[edit]

In January 2016, Fortune estimated the then-32-year-old Shkreli's net worth was at least $45 million but later updated its profile to reflect that "[S]ince this article was published the value of Shkreli's E-Trade account had dropped by more than $40 million."[159] Shkreli leveraged a $4 million E-Trade account for his bail.[160]

In June 2017, Reuters reported that Shkreli had reported his net worth at $70 million after being arrested in 2015 and that his attorney Benjamin Brafman, in a hearing before Judge Kiyo Matsumoto, had conceded that his client still owned shares of Turing Pharmaceuticals worth between $30 and $50 million.[161]

Personal life

[edit]

In December 2020, Shkreli was in a relationship with Christie Smythe, a former reporter for Bloomberg News who broke the news of Shkreli's arrest in 2015. Smythe described their relationship as being "life partners". In October 2021, Smythe said the two had broken up but remained friends.[145][162]

In October 2023, Vanity Fair published an article on Madison Campbell, the CEO of Leda Health.[163] In the article, it was revealed that Campbell had been involved in a romantic relationship with Shkreli between February and August 2023.[163] Campbell says the two bonded over being "healthcare pariahs" but chose to keep her relationship with him private due to his reputation. Shkreli denied Vanity Fair's request for comment and blocked the author of the article on Twitter.[163]

Hobbies and interests

[edit]

Shkreli, an avid League of Legends player, began expressing interest in purchasing an eSports team in May 2014.[164] Enemy eSports rejected a US$1.2 million offer from Shkreli.[165] He later founded his own team, Odyssey eSports, and aimed to qualify for the 2015 North American League of Legends Challenger Series, but the team failed. In August 2015, Odyssey merged with another team to become the organization Team Imagine, with Shkreli becoming chairman of the team. During the merger, the organization signed the Dota 2 team Leviathan.[166][167]

Shkreli won an auction for the Wu-Tang Clan album Once Upon a Time in Shaolin after the single copy of the album was sold via Paddle8 on November 24, 2015, for US$2 million.[105][168] In October 2016, Shkreli said on his Twitter account that he would release the album for free download if Donald Trump won the 2016 United States presidential election and would destroy the album if Hillary Clinton won.[169] He shared the intro and one track, the day after Trump was elected.[170]

In September 2017,[171] Shkreli attempted to sell Once Upon a Time in Shaolin on eBay, with the winning bid passing US$1 million. He was incarcerated before the sale could be completed.[172] In March 2018, following Shkreli's conviction for fraud, a federal court seized assets belonging to him worth $7.36 million, including Once Upon a Time in Shaolin.[173] The feds sold it at auction in 2021 for an undisclosed amount to raise funds for reimbursing victims.[174] In June 2024, Shkreli was sued by a cryptocurrency collective that bought the album for about $5 million; they claimed Shkreli secretly made digital copies in violation of their deal and distributed them to his friends and followers online.[174] On August 26, 2024, a federal judge ordered Shkreli to turn over all copies, including digital, and report the names of anyone he distributed the music to.[174]

References

[edit]
  1. ^ Merle, Renae (March 9, 2018). "Martin Shkreli sentenced to seven years in prison for defrauding investors". The Washington Post. ISSN 0190-8286. Archived from the original on March 9, 2018. Retrieved March 9, 2018.
  2. ^ "No Friends To Celebrate With, Pharma-Bro Throws Himself Lonesome Online Birthday Party". Queerty. March 18, 2016. Archived from the original on July 30, 2018. Retrieved August 23, 2018.
  3. ^ "Social Blade". Social Blade. March 16, 2023. Archived from the original on March 16, 2023. Retrieved May 1, 2024.
  4. ^ a b "About Martin Shkreli". YouTube.
  5. ^ Kolhatkar, Sheelah (July 17, 2017). "The Strange Defense of Martin Shkreli". The New Yorker. Archived from the original on July 11, 2022. Retrieved June 12, 2022.
  6. ^ a b c d McLean, Bethany (December 18, 2015). "Everything You Know About Martin Shkreli Is Wrong – or Is It?". Vanity Fair. ISSN 0733-8899. Archived from the original on July 30, 2018. Retrieved August 23, 2018. He was born on April Fools' Day 1983, to Albanian immigrants
  7. ^ Archived at Ghostarchive and the Wayback Machine: "Shkreli's view on religion (01 Mar 2017)". YouTube.
  8. ^ a b Ortiz, Erik; Dienst, Jonathan; Valiquette, Joe; Hastey, Alicia (December 17, 2015). "FBI Arrests Pharma CEO Martin Shkreli on Securities Fraud Charges". New York: NBC News. Archived from the original on August 3, 2018. Retrieved August 23, 2018.
  9. ^ Creswell, Julie; Clifford, Stephanie; Pollack, Andrew; Goldstein, Matthew; Chen, David (December 17, 2015). "Drug C.E.O. Martin Shkreli Arrested on Fraud Charges". The New York Times. pp. A1, B6. ISSN 0362-4331. Archived from the original on February 5, 2016. Retrieved February 25, 2017. Mr. Shkreli, a pharmaceutical industry entrepreneur...
  10. ^ a b Thomas, Zoe; Swift, Tim (September 23, 2015). "Who is Martin Shkreli – 'the most hated man in America'?". BBC News. London. Archived from the original on December 31, 2015. Retrieved June 21, 2018.
  11. ^ a b Pearson, Erica (March 9, 2015). "Hunter College High School gets record $1M gift from grad". Daily News. New York. Archived from the original on January 24, 2016. Retrieved December 11, 2015.
  12. ^ "Martin Shkreli: the most hated millennial in America". British GQ. January 3, 2017. Archived from the original on December 10, 2019. Retrieved December 10, 2019.
  13. ^ Chen, David W.; Rosenberg, Eli (December 24, 2015) [1st puborn December 18, 2015]. "Martin Shkreli's Arrest Fuels Debate Over $1 Million Donation". The New York Times. p. A17. ISSN 0362-4331. Archived from the original on December 31, 2015. Retrieved February 7, 2016.
  14. ^ "Martin Shkreli, the bad boy of pharma, makes no apologies". The Seattle Times. December 13, 2015. Archived from the original on June 16, 2021. Retrieved June 15, 2021.
  15. ^ a b c d e Pollack, Andrew; Creswell, Julie (September 22, 2015). "Martin Shkreli, the Mercurial Man Behind the Drug Price Increase That Went Viral". The New York Times. p. B1. ISSN 0362-4331. Archived from the original on December 6, 2015. Retrieved February 25, 2017.
  16. ^ "Reich: Even after sentencing, America still has a Shkreli problem". Baltimore Sun. March 14, 2018. Archived from the original on November 4, 2023. Retrieved October 11, 2023.
  17. ^ a b c d e Barrett, Paul (April 17, 2014). "Retrophin's Martin Shkreli, the Biotech Short Seller Who Went Long". Bloomberg Businessweek. ISSN 0007-7135. Archived from the original on December 17, 2015. Retrieved December 17, 2015. Once a Notorious Short Seller, Martin Shkreli Now Sees a Future in Biotech
  18. ^ "Martin Shkreli". TheStreet.com. Archived from the original on December 22, 2015. Retrieved December 17, 2015.
  19. ^ "Shkreli Indictment Portrays Small-Time Fraud". The New York Times. December 18, 2015. Archived from the original on July 8, 2017. Retrieved February 25, 2017.
  20. ^ La Roche, Julia; Jacobs, Peter (December 17, 2015). "Hedge funder Martin Shkreli has been arrested in a securities-fraud investigation" Archived December 17, 2015, at the Wayback Machine, Business Insider, December 2015.
  21. ^ Pollack, Andrew (February 1, 2011). "FDA Declines to Approve Diet Drug". The New York Times. Archived from the original on December 4, 2017. Retrieved February 25, 2017. Shares of Orexigen plunged 72.5 percent on Tuesday, to $2.50
  22. ^ "Former Hedge Fund Manager and New York Attorney Indicted in Multi‑Million‑Dollar Fraud Scheme" (Press release). Federal Bureau of Investigation. December 17, 2015. Archived from the original on December 31, 2015. In February 2011, MSMB Capital failed to settle a short position of more than 11 million shares of Orexigen Therapeutics ... that Merrill Lynch ultimately closed at a loss of over $7 million
  23. ^ Hiltzik, Michael (December 17, 2015). "Martin Shkreli was one terrible investor, SEC document shows". Los Angeles Times. Archived from the original on August 12, 2016. Retrieved August 8, 2016.
  24. ^ a b c United States District Court for the Southern District of New York (October 17, 2015). "EX-99.1, Retrophin, Inc. v. Martin Shkreli". SEC.gov (EDGAR). United States Securities and Exchange Commission. Archived from the original on September 20, 2015. Retrieved September 22, 2015.
  25. ^ Silverman, Ed (September 26, 2015). "Biotech Exec Martin Shkreli Has History of Tough Tactics". The Boston Globe. Archived from the original on September 28, 2015. Retrieved September 28, 2015.
  26. ^ "Hedge Fund Manager Denies CREW Allegations". FINalternatives. July 17, 2012. Archived from the original on March 18, 2017. Retrieved December 18, 2015.
  27. ^ Nussbaum, Alex (October 3, 2011). "MSMB Capital Makes Unsolicited $378M Bid For AMAG Pharmaceuticals". Bloomberg Businessweek. ISSN 0007-7135. Archived from the original on October 20, 2014. Retrieved December 9, 2015.
  28. ^ Herper, Matthew (December 18, 2012). "30 Under 30: Hedge Fund Gadfly Turns Biotech Entrepreneur". Forbes. Archived from the original on November 21, 2017. Retrieved August 8, 2016 – via forbes.com.
  29. ^ Silverman, Ed (December 17, 2015). "Reviled CEO Martin Shkreli arrested on securities fraud charges". STAT. Boston Globe Media Partners.
  30. ^ a b Weintraub, Arlene (October 15, 2015). "Retrophin Sues Founder Martin Shkreli For $65M. His Reply: 'Preposterous'". Forbes. Archived from the original on December 7, 2015. Retrieved December 10, 2015.
  31. ^ "Retrophin: About Us". Archived from the original on December 30, 2011.
  32. ^ https://www.forbes.com/30-under-30/2013/finance/ [bare URL]
  33. ^ "Hall Of Shame: The 10 Most Dubious People Ever To Make Our 30 Under 30 List". Forbes. Archived from the original on November 29, 2023. Retrieved November 29, 2023.
  34. ^ "Forbes publishes 30 Under 30 "Hall of Shame."". The Verge. November 29, 2023. Archived from the original on December 15, 2023. Retrieved February 29, 2024.
  35. ^ "Stephen J. Aselage biography". Bloomberg. September 22, 2015. Archived from the original on September 29, 2015. Retrieved September 22, 2015.
  36. ^ Feuerstein, Adam (August 11, 2014). "Retrophin CEO Under Fire for Twitter Faux Pas". TheStreet.com. Archived from the original on December 24, 2015. Retrieved December 21, 2015.
  37. ^ Milford, Phil; Tracer, Zachary (August 17, 2015). "Retrophin Sues Founder in Latest Fight Over Use of Funds". Bloomberg Businessweek. ISSN 0007-7135. Archived from the original on September 29, 2015. Retrieved September 22, 2015.
  38. ^ Barrett, Paul (October 2, 2014). "Executives: Biotech Company Retrophin Fired CEO Because of Stock Irregularities". Bloomberg Businessweek. ISSN 0007-7135. Archived from the original on November 22, 2015. Retrieved December 10, 2015.
  39. ^ Mangan, Dan (September 22, 2015). "Controversial Drug CEO was Accused of Serious 'Harassment'". CNBC. Archived from the original on November 16, 2015. Retrieved December 10, 2015.
  40. ^ a b Eichenwald, Kurt (September 23, 2015). "Federal Prosecutors Target Martin Shkreli in a Criminal Investigation". Newsweek. Archived from the original on September 26, 2015. Retrieved September 27, 2015.
  41. ^ Barrett, Paul (February 23, 2015). "Biotech's 'Boy Genius' Faces New Allegations of Wrongdoing". Bloomberg Businessweek. ISSN 0007-7135. Archived from the original on November 15, 2015. Retrieved December 10, 2015. Subtitle: Retrophin fired former CEO Martin Shkreli in October, and their new SEC filing reveals more about his apparent misdeeds.
  42. ^ US patent 8673883, "Pantothenate derivatives for the treatment of neurologic disorders"  US patent 9181286, "Pantothenate derivatives for the treatment of neurologic disorders" "Google patents". Archived from the original on December 22, 2015. Retrieved December 23, 2015.
  43. ^ Armental, Maria (November 16, 2020). "WSJ News Exclusive | Retrophin, Founded by Martin Shkreli, Rebrands Itself as Travere Therapeutics". The Wall Street Journal. ISSN 0099-9660. Archived from the original on November 16, 2020. Retrieved November 16, 2020.
  44. ^ Pierson, Brendan (July 13, 2017). "CEO of Martin Shkreli's old company likens him to 'Pied Piper'". Reuters. Archived from the original on August 16, 2017. Retrieved July 17, 2017.
  45. ^ "Retrophin Raises $10.0 Million in Private Placement". retropin.com. Archived from the original on November 10, 2020. Retrieved August 3, 2020.
  46. ^ Lowe, Derek (September 11, 2014). "The Most Unconscionable Drug Price Hike I Have Yet Seen". Science Magazine. In the Pipeline (blog). Archived from the original on June 7, 2016. Retrieved August 9, 2016.
  47. ^ Carroll, John (September 20, 2015). "Why would Martin Shkreli hike an old drug price by 5000%? Only a 'moron' would ask". FierceBiotech. Archived from the original on April 10, 2016. Retrieved March 9, 2018.
  48. ^ "Comparing the US's ten most expensive drugs with prices in the UK". Pharmaceutical Technology. August 22, 2018. Archived from the original on November 1, 2020. Retrieved August 3, 2020.
  49. ^ "How Pharmacies Are Dealing with Daraprim After Martin Shkreli's Arrest". Fortune. December 18, 2015. Archived from the original on September 6, 2016. Retrieved August 8, 2016.
  50. ^ Elvidge, Suzanne (September 29, 2016). "Imprimis shuts down Texas plant, axes 8% of jobs". BioPharma Dive. Archived from the original on March 10, 2018. Retrieved March 9, 2018.
  51. ^ Weintraub, Arlene (February 27, 2015). "Gadfly Pharma Investor Shkreli Starts Anew After Ousting From Retrophin". Forbes. Archived from the original on September 25, 2015. Retrieved September 24, 2015.
  52. ^ a b c Surowiecki, James (October 12, 2015). "Taking on the Drug Profiteers". The Financial Page. The New Yorker. Archived from the original on December 11, 2015. Retrieved December 10, 2015.
  53. ^ Lowe, Derek (September 21, 2015). "Martin Shkreli Has One Idea, And It's a Bad One". Science Translational Medicine. Science Magazine. In the Pipeline (blog). OCLC 5942328021. Archived from the original on December 11, 2015. Retrieved December 9, 2015.
  54. ^ Norviel, Vern; Hoffmeister, David M. (September 30, 2015). "A Look At The Legality Behind Daraprim's Price Spike". Law360. Archived from the original on August 18, 2016. Retrieved August 8, 2016.
  55. ^ Timmerman, Luke (September 23, 2015). "A Timeline of the Turing Pharma Controversy". Pharma & Healthcare. Forbes. Archived from the original on December 11, 2015. Retrieved December 10, 2015.
  56. ^ Mitchell, Andrea; Helsel, Phil (September 23, 2015). "Drug CEO Will Lower Price of Daraprim After Hike Sparked Outrage". NBC News. National Broadcasting Co. Archived from the original on September 23, 2015. Retrieved September 23, 2015.
  57. ^ a b c Pollack, Andrew (September 20, 2015). "Drug Goes From $13.50 a Tablet to $750, Overnight". Business Day. The New York Times. Archived from the original on December 16, 2015. Retrieved December 10, 2015.
  58. ^ Masur, Henry, Brooks, John T, Benson, CA, Holmes, KK, et al. (February 2014). "Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents". Clinical Infectious Diseases. 58 (9): 1308–11. doi:10.1093/cid/ciu094. PMC 3982842. PMID 24585567. Updated Guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America
  59. ^ a b c Muoio, Dave (September 17, 2015). "Daraprim price jump raises concerns among ID groups, providers". Healio. Infectious Disease News. Archived from the original on December 11, 2015. Retrieved December 10, 2015.
  60. ^ Tirrell, Meg (December 1, 2015). "Express Scripts, Imprimis to offer $1 Daraprim alternative". CNBC. Archived from the original on August 7, 2020. Retrieved December 23, 2015.
  61. ^ "About Healio". Healio. December 10, 2015. Archived from the original on December 1, 2015. Retrieved December 10, 2015.
  62. ^ a b Calderwood, Stephen B.; Adaora Adimora (September 8, 2015). Letter from Stephen B. Calderwood, MD, FIDSA (President, IDSA) and Adaora Adimora, MD, MPH, FIDSA (Chair, HIVMA) to Mssrs. Tom Evegan (Head of Managed Markets) and Kevin Bernier (National Director Alliance Development & Public Affairs), both of Turing Pharmaceuticals (PDF) (Report). Arlington, Virginia: Infectious Diseases Society of America (IDSA), HIV Medicine Association (HIVMA). Archived from the original (PDF) on March 13, 2016. Retrieved December 10, 2015.
  63. ^ Kliff, Sarah (September 22, 2015). "A Drug Company Raised a Pill's Price 5,500 Percent Because, in America, It Can". Vox Explainers. Vox. Archived from the original on December 10, 2015. Retrieved December 9, 2015.
  64. ^ Bloomfield, Doni (September 22, 2015). "Drug CEO Targeted by Clinton Is Criticized by Drug Lobby". Bloomberg Businessweek. ISSN 0007-7135. Archived from the original on September 24, 2015. Retrieved September 23, 2015.
  65. ^ Long, Heather; Matt Egan; Dodley Dominique (September 22, 2015). "Meet the guy behind the $750 AIDS drug". Money. CNN. Archived from the original on September 24, 2015. Retrieved September 23, 2015.
  66. ^ Eunjung Cha, Ariana (September 22, 2015). "CEO who raised price of old pill more than $700 calls journalist a 'moron' for asking why". The Washington Post. Archived from the original on September 23, 2015. Retrieved September 23, 2015.
  67. ^ LoGiurato, Brett (September 2015). "Donald Trump trashes former hedge-fund guy who jacked up drug price: 'He looks like a spoiled brat'". Business Insider. Archived from the original on September 25, 2015. Retrieved September 23, 2015.
  68. ^ Tirrell, Meg (October 22, 2015). Health Groups Appeal to Turing on Drug Price. CNBC (news video). Englewood Cliffs, NJ. Archived from the original on December 22, 2015. Retrieved December 10, 2015.
  69. ^ An open appeal to Turing Pharmaceuticals (Report). Arlington, VA: Infectious Diseases Society of America (IDSA). November 3, 2015. Retrieved December 10, 2015.
  70. ^ Walters, Joanna (September 25, 2015). "Label Cuts Ties With Hedge Fund Man Who Boosted AIDS Drug Price 5,000%". Music Industry. The Guardian. London, UK. Archived from the original on September 29, 2015. Retrieved September 28, 2015. Subtitle: Collect Records says it is impossible to continue having Martin Shkreli as investor over raising Daraprim price from $13.50 per tablet to $750.
  71. ^ Fu, Scarlet (September 21, 2015). Drug Goes From $13.50 to $750 Overnight. Bloomberg (video interview). Archived from the original on July 5, 2022. Retrieved December 10, 2015.
  72. ^ Ramsey, Lydia (September 22, 2015). "A pharma CEO tried to defend his decision to jack up the price of a critical drug by 5,000 – and it backfired". Business Insider. Archived from the original on October 10, 2015. Retrieved October 12, 2015.
  73. ^ "Company hikes price of popular drug". Reuters (video). September 22, 2015. Archived from the original on October 2, 2015.
  74. ^ a b Pollack, Andrew (November 24, 2015). "Turing Refuses to Lower List Price of Toxoplasmosis Drug". The New York Times. p. B4. ISSN 0362-4331. Archived from the original on November 25, 2015. Retrieved February 7, 2016.
  75. ^ Lydia, Ramsey (October 12, 2015). "Pharma CEO Martin Shkreli failed to respond to Bernie Sanders about his drug hike – and Sanders is not happy". Business Insider. Archived from the original on December 22, 2015. Retrieved December 17, 2015.
  76. ^ Sanders, Bernie (September 21, 2015). 2015-09-01 EEC Sanders to Turing Pharmaceuticals (PDF) (Report). United States House Committee on Oversight and Government Reform (Democratic Party). Archived from the original (PDF) on December 12, 2016. Retrieved October 9, 2015.
  77. ^ Wilson, Megan R. (October 2, 2015). "Drug firm maligned for 5,000 percent price hike turns to K Street for help". Business & Lobbying. The Hill. Archived from the original on December 5, 2015. Retrieved December 9, 2015.
  78. ^ Ho, Catherine (October 7, 2015). "Working For 'The Most Hated Man in America'". The Washington Post. Archived from the original on December 23, 2015. Retrieved December 10, 2015.
  79. ^ Tannahill, Jason (October 9, 2015). "PR Man Allan Ripp Representing The 'Most Hated Man in America'". Everything P.R. Archived from the original on October 14, 2015. Retrieved October 12, 2015.
  80. ^ a b Fox, Maggie (October 22, 2015). "Competitor to Offer $1 Pill After Turing Price Hike Outrage". Health. NBC News. Archived from the original on December 10, 2015. Retrieved December 10, 2015.
  81. ^ Langreth, Robert (November 24, 2015). "Drugmaker Turing Suggests It Won't Cut List Price of Daraprim". Bloomberg Businessweek. ISSN 0007-7135. Archived from the original on November 28, 2015. Retrieved December 10, 2015.
  82. ^ "Turing Reneges on Drug Price Cut, Rival's Version Sells Well". Business. The Washington Post. Associated Press. November 25, 2015. Archived from the original on November 26, 2015. Retrieved November 27, 2015.
  83. ^ Corporation Filings 08/27/2017 to 09/03/2017. Secretary of State (Report). Newsletters. State of Louisiana. Archived from the original on January 15, 2022. Retrieved September 24, 2017.
  84. ^ Copeland, Rob; Bradley Hope (March 7, 2019). "Martin Shkreli Steers His Old Company From Prison – With Contraband Cellphone". The Wall Street Journal. Archived from the original on March 8, 2019. Retrieved March 8, 2019.
  85. ^ Bach, Natasha (March 7, 2019). "Martin Shkreli Still Running his Business – from Prison". Fortune. Archived from the original on March 10, 2019. Retrieved March 8, 2019.
  86. ^ Mangan, Dan (April 24, 2019). "'Pharma bro' Martin Shkreli moved from federal prison after claim he was running drug company with banned cellphone". CNBC. Archived from the original on July 19, 2019. Retrieved July 19, 2019.
  87. ^ Bomey, Nathan (March 8, 2019). "'Pharma Bro' Martin Shkreli facing Bureau of Prisons investigation into his behavior". USA Today. Archived from the original on July 19, 2019. Retrieved July 19, 2019.
  88. ^ Knauth, Dietrich, "Martin Shkreli-founded drug company files for bankruptcy" Archived November 14, 2023, at the Wayback Machine, reuters.com, May 10, 2023. Retrieved 2023-05-14.
  89. ^ "Vyera Pharmaceuticals, LLC". Federal Trade Commission. January 27, 2020. Archived from the original on December 9, 2021. Retrieved December 9, 2021.
  90. ^ "'Pharma Bro' firm reaches $40M settlement in gouging case". Associated Press. December 8, 2021. Archived from the original on December 9, 2021. Retrieved December 9, 2021.
  91. ^ Koenig, Bryan (December 7, 2021). "Former Shkreli Co. Inks Deal Worth Up To $40M With FTC, AGs – Law360". Law360. Archived from the original on December 9, 2021. Retrieved December 9, 2021.
  92. ^ "KaloBios stock rockets after investment from Shkreli". Yahoo Finance. November 19, 2015. Archived from the original on November 22, 2015.
  93. ^ "KaloBios Pharmaceuticals, Inc. Appoints Martin Shkreli CEO and Announces New Financing" (Press release). KaloBios. November 19, 2015. Archived from the original on December 20, 2015. Retrieved December 18, 2015.
  94. ^ Weintraub, Arlene (November 19, 2015). "Here's Why Shkreli Is Going To Have His Hands Full Trying To Save KaloBios". Forbes. Archived from the original on November 23, 2015. Retrieved December 10, 2015.
  95. ^ Rosenfeld, Everett (December 21, 2015). "Martin Shkreli fired by KaloBios Pharmaceuticals". CNBC. Archived from the original on December 21, 2015. Retrieved December 21, 2015.
  96. ^ "Martin Shkreli's KaloBios files for bankruptcy". CNBC. Reuters. Archived from the original on January 5, 2016. Retrieved December 30, 2015.
  97. ^ "'Pharma bro' Martin Shkreli is fresh out of prison with a new Web3-crypto 'drug discovery' business". Archived from the original on December 23, 2023. Retrieved February 29, 2024.
  98. ^ "Pharma Bro crypto crash raises fears but doesn't deter investors". Archived from the original on August 27, 2022.
  99. ^ a b Johnson, Carolyn Y., "'Pharma bro' Martin Shkreli refuses to testify at congressional hearing, calls lawmakers 'imbeciles' in tweet" Archived February 4, 2016, at the Wayback Machine, The Washington Post (February 4, 2015).
  100. ^ Developments in the Prescription Drug Market: Oversight. Committee on Oversight and Government Reform (Report). United States House of Representatives. February 4, 2016. Archived from the original on March 4, 2017. Retrieved February 7, 2016.
  101. ^ Testimony of Nancy Retzlaff Chief Commercial Officer, Turing Pharmaceuticals (PDF). Committee on Oversight and Government Reform (Report). United States House of Representatives. January 26, 2016. Archived from the original (PDF) on February 11, 2017. Retrieved February 4, 2016.
  102. ^ Statement of Howard B. Schiller interim Chief Executive Officer and Director, Valeant Pharmaceuticals International, Inc (PDF). Committee on Oversight and Government Reform (Report). United States House of Representatives. February 4, 2016. Archived from the original (PDF) on February 11, 2017. Retrieved February 4, 2016.
  103. ^ "Drug company boss Martin Shkreli refuses to testify to Congress". The Guardian. London, UK. February 4, 2016. Archived from the original on January 28, 2017. Retrieved December 12, 2016.
  104. ^ "Watch Martin Shkreli Troll Congress by Taking the Fifth Over and Over Again". MoneyBox blog. Slate.com. February 4, 2016. Archived from the original on February 13, 2016. Retrieved February 12, 2016.
  105. ^ a b Leonard, David (December 9, 2015). "Who Bought The Most Expensive Album Ever Made?". Bloomberg Businessweek. ISSN 0007-7135. Archived from the original on December 30, 2017. Retrieved April 2, 2019.
  106. ^ Pollack, Andrew; Huetteman, Emmarie (February 4, 2016). "Martin Shkreli Invokes the Fifth Amendment During Grilling by Congress". The New York Times. p. B1. ISSN 0362-4331. Archived from the original on February 4, 2016.
  107. ^ Smythe, Christie; Geiger, Keri (December 17, 2015). "Shkreli, CEO Reviled for Drug Price Gouging, Arrested on Securities Fraud Charges". Bloomberg Businessweek. ISSN 0007-7135. Archived from the original on March 4, 2017. Retrieved March 9, 2017.
  108. ^ Former Hedge Fund Manager and New York Attorney Indicted in Multimillion Dollar Fraud Scheme. U.S. Attorney's Office, Eastern District of New York (Report). United States Department of Justice. December 17, 2015. Archived from the original on November 11, 2020. Retrieved November 22, 2020.
  109. ^ Grim, Ryan; Young, Jeffrey (September 23, 2016) [2015]. "Drug‑Price Gouging Hedge Fund Guy May Be Even Worse Than You Thought, SEC Documents Show". HuffPost. Archived from the original on December 20, 2015.
  110. ^ Copeland, Rob (December 21, 2015). "Martin Shkreli Says Drug-Price Hikes Led to Arrest". The Wall Street Journal. ISSN 0099-9660. Archived from the original on December 21, 2015. Retrieved December 21, 2015.
  111. ^ Goldstein, Matthew; Stevenson, Alexandra (February 3, 2016). "Martin Shkreli Appears to Adopt a New Legal Strategy: Silence". The New York Times. ISSN 0362-4331. Archived from the original on July 8, 2017. Retrieved February 25, 2017.
  112. ^ Silverstein, Jason (February 2, 2016). "Shkreli hires Brafman, high-profile attorney". New York Daily News. LCCN sn83030450. Archived from the original on February 4, 2016. Retrieved February 4, 2016.
  113. ^ "Public enemy". Harper's Magazine. September 2017. Archived from the original on October 1, 2019. Retrieved September 30, 2019.
  114. ^ Merle, Renae (July 8, 2017). "The fascinating legal argument at the heart of the Martin Shkreli 'Pharma Bro' trial". The Washington Post. Archived from the original on July 10, 2017. Retrieved July 10, 2017.
  115. ^ Merle, Renae (July 5, 2017). "Prosecutors want Martin Shkreli to stop talking". The Washington Post. Archived from the original on July 10, 2017. Retrieved July 10, 2017.
  116. ^ Merle, Renae (July 5, 2017). "Judge to Martin Shkreli: Keep your mouth shut". The Washington Post. Archived from the original on July 10, 2017. Retrieved July 10, 2017.
  117. ^ "Martin Shkreli trial verdict: Guilty on 3 of 8 counts". CBS News. Archived from the original on May 27, 2020. Retrieved April 17, 2020.
  118. ^ "'Pharma Bro' Martin Shkreli 'delighted' by verdict in securities fraud trial". ABC News. August 4, 2017. Archived from the original on April 18, 2020. Retrieved August 4, 2017.
  119. ^ Clifford, Stephanie (September 13, 2017). "Martin Shkreli Is Jailed for Seeking a Hair From Hillary Clinton". The New York Times. Archived from the original on September 13, 2017. Retrieved September 14, 2017.
  120. ^ a b "Pharma Bro jailed after judge declares him a 'danger to society'". New York Post. September 13, 2017. Archived from the original on September 13, 2017. Retrieved September 13, 2017.
  121. ^ Mangan, Dan (September 6, 2017). "Martin Shkreli posts 'bounty' for Hillary Clinton's hair; puts Wu-Tang Clan album on sale". CNBC. Archived from the original on September 14, 2017. Retrieved September 14, 2017.
  122. ^ "'Pharma Bro' apologizes as judge weighs locking him up for Clinton trolling". New York Post. September 12, 2017. Archived from the original on January 21, 2018. Retrieved December 19, 2017.
  123. ^ a b Merle, Renae (September 13, 2017). "Martin Shkreli jailed after Facebook post about Hillary Clinton". The Washington Post. Archived from the original on September 14, 2017. Retrieved September 14, 2017.
  124. ^ a b Mangan, Dan (April 18, 2018). "Pharma bro fraudster Martin Shkreli sent to federal prison in New Jersey after being denied minimum security camp". CNBC. Archived from the original on September 13, 2018. Retrieved August 23, 2018.
  125. ^ "Martin Shkreli back in federal custody after dumb Facebook post about stealing Clinton's hair". The Daily Dot. September 14, 2017. Archived from the original on September 30, 2017. Retrieved September 30, 2017.
  126. ^ Hays, Tom, & Colleen Long, 'Pharma Bro' Martin Shkreli cries in court, is sentenced to 7 years for securities fraud Archived April 13, 2020, at the Wayback Machine, Associated Press, March 9, 2018.
  127. ^ "'Pharma Bro' Martin Shkreli sentenced to seven years". BBC News. March 9, 2018. Archived from the original on June 18, 2018. Retrieved March 9, 2018.
  128. ^ Clifford, Stephanie (March 9, 2018). "Martin Shkreli Sentenced to 7 Years in Prison for Fraud". The New York Times. ISSN 0362-4331. Archived from the original on March 29, 2018. Retrieved March 31, 2018.
  129. ^ a b Mole, Beth (July 18, 2019). "Shkreli stays in jail; Infamous ex-pharma CEO quickly loses appeal". Ars Technica. Archived from the original on July 19, 2019. Retrieved July 19, 2019.
  130. ^ a b Dolmetsch, Chris; Hurtado, Patricia (July 18, 2019). "Martin Shkreli's Conviction Is Upheld by U.S. Appeals Court". Bloomberg News. Archived from the original on July 19, 2019. Retrieved July 19, 2019.
  131. ^ "Martin Shkreli must forfeit $7.4 million, including infamous Wu Tang album". CNN. March 5, 2018. Archived from the original on October 27, 2020. Retrieved March 6, 2017.
  132. ^ "Shkreli Ordered by U.S. Judge to Forfeit Almost $7.4 Million". Bloomberg News. March 5, 2018. Archived from the original on March 9, 2018. Retrieved March 9, 2018.
  133. ^ Mangan, Dan (April 10, 2018). "Martin Shkreli ordered to pay $388,000 in restitution to investor". CNBC. Archived from the original on May 8, 2018. Retrieved May 7, 2018.
  134. ^ https://www.nytimes.com/2021/10/20/arts/music/wu-tang-clan-once-upon-a-time-in-shaolin.html
  135. ^ Limbong, Andrew (July 27, 2021). "Wu-Tang Clan Album Once Owned By Martin Shkreli Sold By U.S. Government". NPR. Archived from the original on August 9, 2021. Retrieved August 8, 2021.
  136. ^ Abadi, Mark (September 15, 2017). "Martin Shkreli is in prison – and could end up facing a longer sentence". Business Insider. Archived from the original on October 10, 2017. Retrieved October 8, 2017.
  137. ^ Mangan, Dan (March 27, 2018). "Pharma bro Martin Shkreli appeals fraud conviction as judge mulls restitution award". CNBC. Archived from the original on March 30, 2018. Retrieved March 29, 2018.
  138. ^ "'Pharma bro' fraudster Martin Shkreli: I want to serve prison in a minimum-security federal camp". wn.com. Archived from the original on April 5, 2018. Retrieved April 4, 2018.
  139. ^ a b Aaron Gregg (May 15, 2022). "Martin Shkreli, Wall Street's 'Pharma Bro,' is out of prison early". Washington Post. Archived from the original on May 19, 2022. Retrieved May 18, 2022.
  140. ^ Mangan, Dan (September 6, 2019). "Martin Shkreli sues investor over $420,000 debt that the 'Pharma Bro' owes the man's dad". CNBC. Archived from the original on September 8, 2019. Retrieved September 9, 2019.
  141. ^ Hurtado, Patricia. "Even Behind Bars, Martin Shkreli Is Still Filing Lawsuits". Bloomberg Law. Archived from the original on August 3, 2020. Retrieved September 9, 2019.
  142. ^ Sisak, Michael R.; Peltz, Jennifer (January 14, 2022). "Shkreli ordered to return $64M, is barred from drug industry". Associated Press. Archived from the original on January 14, 2022. Retrieved January 14, 2022.
  143. ^ "Martin Shkreli's ex Christie Smythe on his release: 'I'd love to see him'". May 18, 2022. Archived from the original on January 29, 2024. Retrieved November 19, 2023.
  144. ^ "Martin Shkreli's ex Christie Smythe: 'If he manipulated me, I'm glad it worked'". October 3, 2021. Archived from the original on December 18, 2021. Retrieved November 19, 2023.
  145. ^ a b Clifford, Stephanie (December 20, 2020). "The Journalist and the Pharma Bro". Elle. Archived from the original on December 21, 2020. Retrieved December 21, 2020.
  146. ^ "'Delusional' Martin Shkreli denied prison release by judge". San Francisco Chronicle. New York City. May 17, 2020. Retrieved May 18, 2020. Matsumoto rejected that, relaying concerns of probation officials that Shkreli's claim that he could develop a cure for coronavirus that 'so far eluded the best medical and scientific minds in the world working around the clock' is 'delusional self-aggrandizing behavior.'[permanent dead link‍]
  147. ^ Sisak, Michael R. (April 24, 2021). "'Pharma Bro' Shkreli loses 2nd bid for early prison release". Associated Press. Archived from the original on August 8, 2021. Retrieved August 8, 2021.
  148. ^ "Martin Shkreli 'Pharma bro' released early from prison". BBC News. May 18, 2022. Archived from the original on May 18, 2022. Retrieved May 19, 2022.
  149. ^ Aditi Bharade, 'Pharma bro' Martin Shkreli is out of jail and living with his sister in Queens, and now earns $2,500 a month as a law firm consultant Archived July 16, 2023, at the Wayback Machine, Business Insider (May 24, 2023).
  150. ^ Erik Larson & Patricia Hurtado, Ex-'Pharma Bro' Shkreli Consulting While Living in Queens (2) Archived July 16, 2023, at the Wayback Machine, Bloomberg Law (May 24, 2023).
  151. ^ Shkreli, Martin (May 24, 2023). "How the media lies about me: Bloomberg & Politico". Martin's Newsletter. Archived from the original on January 10, 2024. Retrieved August 16, 2023.
  152. ^ a b c Mangan, Dan (April 23, 2018). "Fight brews over Shkreli's Wu-Tang album as 'pharma bro' gets banned by securities industry". CNBC. Archived from the original on April 24, 2018. Retrieved April 24, 2018.
  153. ^ a b c FTC v. Skreli Archived July 16, 2023, at the Wayback Machine, 581 F. Supp. 3d 579 (S.D.N.Y. 2022).
  154. ^ Robbins, Rebecca; Kang, Cecilia (January 14, 2022). "Martin Shkreli is barred from the drug industry and ordered to repay $64.6 million". The New York Times. Archived from the original on January 14, 2022. Retrieved January 15, 2022.
  155. ^ Jeong, Andrew, 'Pharma Bro' Martin Shkreli ordered to repay $64 million and banned for life from drug industry Archived January 15, 2022, at the Wayback Machine, Washington Post (January 15, 2021).
  156. ^ Mangan, Dan (October 7, 2024). "Supreme Court rejects Martin Shkreli fine appeal". CNBC. Retrieved October 7, 2024.
  157. ^ Securities & Exchange Commission v. Shkreli Archived July 16, 2023, at the Wayback Machine, No. 15-CV-7175 (E.D.N.Y. 2022).
  158. ^ Godoy, Jody (February 23, 2022). "U.S. judge bans Martin Shkreli from running public companies". Reuters. Archived from the original on February 24, 2022. Retrieved February 24, 2022.
  159. ^ Shkreli net worth estimate Archived February 15, 2017, at the Wayback Machine, fortune.com, January 8, 2016; accessed April 19, 2017.
  160. ^ Shkreli's etrade account has lost $40 million Archived February 20, 2017, at the Wayback Machine, fortune.com; accessed February 18, 2017.
  161. ^ "U.S. judge wants more details on ex-drug executive Shkreli's finances". Reuters India. Archived from the original on June 20, 2017. Retrieved June 27, 2017.
  162. ^ "Martin Shkreli's ex Christie Smythe: 'If he manipulated me, I'm glad it worked'". New York Post. October 3, 2021. Archived from the original on December 18, 2021. Retrieved December 18, 2021.
  163. ^ a b c ""Are You Dating Martin Shkreli?": How A Pharma Bro Fling Upended Madison Campbell's Start-Up". Vanity Fair. October 16, 2023. Archived from the original on October 16, 2023. Retrieved October 27, 2023.
  164. ^ Wolf, Jacob (May 6, 2015). "Millionaire pharmaceutical CEO set to shake up Challenger scene with new team". The Daily Dot. Archived from the original on September 23, 2015. Retrieved August 27, 2015.
  165. ^ Weber, Alexandre ("Druppet") (May 4, 2015). "Enemy Esports Turned Down $1.2 Million for Their League of Legends Team". eSports Go. Retrieved September 24, 2015.[permanent dead link‍]
  166. ^ Wolf, Jacob (August 7, 2015). "Imagine and Odyssey merge, add Leviathan Dota 2 squad". The Daily Dot. Archived from the original on September 23, 2015. Retrieved August 27, 2015.
  167. ^ Ciubotaru, Andra (August 18, 2015). "Recently merged League of Legends organization adds Team Leviathan Dota 2 squad". DotaBlast. Archived from the original on September 25, 2015. Retrieved August 27, 2015.
  168. ^ Greenburg, Zack O'Malley (November 24, 2015). "Wu-Tang Clan Secret Album Sold By Paddle8, But To Whom?". Forbes. Archived from the original on November 28, 2015. Retrieved December 23, 2015.
  169. ^ "Martin Shkreli Will Drop Unreleased Wu-Tang Clan Music If Donald Trump Wins Presidential Election". xxlmag. October 2016. Archived from the original on November 9, 2016. Retrieved November 9, 2016.
  170. ^ "Hell Freezes Over as Martin Shkreli Performs a Public Service". Gizmodo. November 9, 2016. Archived from the original on September 14, 2017. Retrieved September 9, 2017.
  171. ^ "A Timeline of Events Since Martin Shkreli Purchased Wu Tang Clan's 'Once Upon a Time in Shaolin'". Billboard. Archived from the original on April 24, 2019. Retrieved July 14, 2019.
  172. ^ Greenburg, Zack O'Malley. "Why Jeff Sessions May Control The Fate Of Wu-Tang's Secret Album". Forbes. Archived from the original on September 14, 2019. Retrieved July 14, 2019.
  173. ^ Beaumont-Thomas, Ben (March 6, 2018). "Martin Shkreli's $2 M Wu-Tang Clan album seized by federal court". The Guardian. London, UK. ISSN 0261-3077. Archived from the original on May 16, 2019. Retrieved July 14, 2019.
  174. ^ a b c Neumeister, Larry (August 26, 2024). "Judge orders Martin Shkreli to turn over all copies of unreleased Wu-Tang Clan album". AP News. Retrieved August 26, 2024.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Martin_Shkreli&oldid=1258870703#Retrophin"